outperform price
earn model updat
report earn morn total
product-rel revenu million slightli
consensu million
jakafi sale million light compar
consensu in-lin expect grew
jakafi sale vs major
revenu growth due increas volum reiter
jakafi guidanc billion
announc posit data ruxolitinib cream
vitiligo start trial later year data
present confer vitiligo
repres patient opportun current
end co-fund olumi instead choos
re-alloc capit late stage opportun
previous co-fund
post-poc
baricitinib develop increment royalti
top base royalti expect see
royalti gradual come result
reduc guidanc million reflect
remain optimist valu jak franchis
inci potenti expand new indic
although take detour cancer i/o cost
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
model updat lower olumi revenu royalti
reduc expens due end co-
fund agreement net effect pt move
track rel beat/miss
commentari around product serial around quarter includ
yoy growth
yoy growth
yoy growth mf
yoy growth pv
million
inventori normal
inventori normal
jakafi guidanc
pdufa extend
wind
pembro
fda approv mg
dose mg
adcom sale
sale reflect
bari data atop
dermat expect
derm result
result expect
decis longer
particip co-
fund
develop
result later year
longer initi
serial guidanc updat
chang fair valu
addit commentari key programs/pipelin
multipl jak combo underway mf
multipl jak combo underway mf
multipl jak combo underway mf
multipl jak combo underway mf
multipl jak combo underway mf
snda accept prioriti review
pdufa feb data
expect
snda accept prioriti review
extend may
expect
snda accept prioriti review
extend may
expect
vitiligo on-going data expect
vitiligo on-going data expect
 halt lung cancer trial
convert phase random
announc top-line failur echo-
analysi on-going
 halt lunger cancer trial
convert phase random
trial initi
approv mg dose us
sle publish lancet
underway alopecia begin
citadel dlbcl meet
respons criteria studi extend
fl mzl mcl continu
atop dermat alopecia
begin
atop derm expect
initi sle sever
present full atop derm expect
top-line result
studi initi sle
arthriti prepar
present full atop derm expect
top-line result
studi initi sle
citadel program monotherapi fl
citadel program monotherapi fl
citadel program monotherapi fl
citadel program monotherapi fl
phase dose escal
combin tagrisso
phase dose escal
combin tagrisso
phase gravita underway
nave acut gvhd combin
phase gravita underway
nave acut gvhd combin
phase gravita expect
begin chronic gvhd
phase dose escal
combin tagrisso
expect
expect
expect
phase gravita expect
begin chronic gvhd
nda submiss expect
nv evalu data
nda submiss expect
nda submiss expect
cholangiocarcinoma/bladd studi
nda submiss expect
nda submiss expect
patient pivot trial
patient pivot trial
bladder program initi tumor-
bladder program initi tumor-
nv evalu data potenti
monotherapi on-going msi-high
nv submit nda
nv submit nda
nv submit nda
cancer expect begin
preclin data oral inhibitor
patient oral inhibitor
dose escal complet
focu combin
complet focu
combin therapi
gitr clinic
inhibitor clinic develop
inhibitor clinic develop
pt base dcf use discount rate appli commerci
stage biotech compani termin growth rate includ contribut jakafi et gvhd well
olumi also includ meaning gener catch-al line item captur program fgfr inhibitor
risk includ increas competit threat jakafi/olumi continu aggress develop spend jakafi
patent expiri approach next decad
articl articl
time dissemin april
analyst josh schimmer shenston huang maneka mirchandaney primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
